Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.69 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295703 | 0.92 | CHEK1 (0.71) | CHEK1NR4A2 | |
| SCHEMBL4292128 | 0.89 | CHEK1 (0.67) | CHEK1NR4A2AXL | |
| SCHEMBL4296990 | 0.88 | CHEK1 (0.65) | CHEK1NR4A2 | |
| SCHEMBL4294428 | 0.88 | CHEK1 (0.65) | CHEK1NR4A2 | |
| SCHEMBL4294720 | 0.87 | CHEK1 (0.62) | CHEK1NR4A2ACLYDHODHCDK8 | |
| SCHEMBL4289781 | 0.87 | CHEK1 (0.62) | CHEK1NR4A2CDK8 | |
| SCHEMBL4291903 | 0.87 | CHEK1 (0.62) | CHEK1NR4A2CDK8PIM1PIM3 | |
| SCHEMBL4300984 | 0.87 | CHEK1 (0.64) | CHEK1NR4A2 | |
| SCHEMBL4288965 | 0.87 | CHEK1 (0.50) | CHEK1DHODH | |
| SCHEMBL13659540 | 0.86 | CHEK1 (0.73) | CHEK1NR4A2DHODHPIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885NR4A2 2243/4885AXL 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.